New hope for aggressive brain cancer: combo therapy enters phase 2 trial
Disease control
Recruiting now
This study tests whether adding silevertinib (an oral targeted therapy) to standard chemotherapy (temozolomide) helps people with a specific type of newly diagnosed glioblastoma live longer without their cancer growing. About 162 adults whose tumors have certain genetic markers (…
Phase: PHASE2 • Sponsor: Black Diamond Therapeutics, Inc. • Aim: Disease control
Last updated May 11, 2026 20:54 UTC